YYYanliang Yu

Yanliang Yu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yanliang Yu has a total of 10 co-authors. Here are the top co-authors by number of shared publications:

  • Chuanzhong Yang

    Department of Neonatology, Shenzhen Maternity and Child Healthcare Hospital, The First School of Clinical Medicine, Southern Medical University, Shenzhen, China

    2 shared publications
  • Bingchun Lin

    Department of Neonatology and Neonatal Intensive Care Unit, Affiliated Shenzhen Maternity and Child Healthcare Hospital, Southern Medical University, Shenzhen 518028, China

    1 shared publication
  • Bingchun Lin

    Department of Neonatology, Affiliated Shenzhen Maternity & Child Healthcare Hospital, Southern Medical University, Shenzhen, Guangdong Province, China

    1 shared publication
  • Haifeng Zong

    Department of Neonatology and Neonatal Intensive Care Unit, Affiliated Shenzhen Maternity and Child Healthcare Hospital, Southern Medical University, Shenzhen 518028, China

    1 shared publication
  • Hongyan Sun

    Neonatal Intensive Care Unit, Shenzhen Maternity and Child Healthcare Hospital, Women and Children’s Medical Center, Southern Medical University, Shenzhen 518028, China

    1 shared publication
  • Jie Zhao

    Department of Neonatology and Neonatal Intensive Care Unit, Affiliated Shenzhen Maternity and Child Healthcare Hospital, Southern Medical University, Shenzhen 518028, China

    1 shared publication

Latest Publications

  • Open Access

    Continuous renal replacement therapy in a neonate with methylmalonic acidemia and severe hyperammonemia: A case report

    by Bingchun Lin, Yichu Huang, Yanliang Yu, Xiaoyun Xiong, Chuanzhong Yang

    Background: Methylmalonic acidemia (MMA) is a rare disease that is often misdiagnosed and overlooked. Metabolic acidosis and severe hyperammonemia are severe morbidities of MMA that demand immediate treatment. Case-diagnosis: Here, we describe an MMA neonate with severe hyperammonemia and acidosis that was successfully rescued by continuous renal replacement therapy. A 6-day-old male neonate, with a gestational age of 39 + 3 weeks and a birth weight of 2880 g, was admitted to the emergency with the symptoms of “cyanosis of the face and coma for 2 hours.” The infant was suffering from hypoglycemia, hypocalcemia, severe hyperammonemia, and severe metabolic acidosis. After admission, the blood ammonia continued to rise, and continuous renal replacement therapy was promptly administered until the patient gradually regained consciousness. Blood tandem mass spectrometry and profiles revealed that methylmalonic acid and methyl citrate levels were significantly enhanced. Two heterozygous mutations were detected in the MUT gene, confirming the diagnosis of methylmalonic acidemia mut. Conclusions: The patient’s symptoms gradually improved after receiving vitamin B12, l-carnitine, and specialized milk feeding. The patient was successfully discharged from the hospital after 41 days.


  • Open Access

    The Predictive Value of Lung Ultrasound Score on Hemodynamically Significant Patent Ductus Arteriosus among Neonates ≤25 Weeks

    by Haifeng Zong, Zhifeng Huang, Bingchun Lin, Jie Zhao, Yongping Fu, Yanliang Yu, Hongyan Sun, Chuanzhong Yang

    Lung ultrasound (LU) is increasingly used to diagnose and monitor neonatal pulmonary disorders; however, its role in hemodynamically significant patent ductus arteriosus (hsPDA) has not been elucidated. This prospective study investigated the predictive value of the LU score (LUS) for hsPDA in preterm infants with gestational age (GA) ≤ 25 weeks. Preterm infants with GA ≤ 25 weeks were enrolled in this study. LU was conducted on the fourth day of life (DOL). Six lung regions in every lung were scanned, with each region rated as 0–4 points. The performance of the LUS in predicting hsPDA among infants aged ≤25 weeks was analyzed by plotting the receiver operating characteristic (ROC) curve. A total of 81 infants were included in this study. GA, birth weight (BW), gender, Apgar score, delivery mode, antenatal steroids, meconium-stained amniotic fluid, premature rapture of membrane, and early-onset sepsis were not significantly different, but infants in the hsPDA group had increased LUS (38.2 ± 2.8 vs. 30.3 ± 4.3, p < 0.001) compared with non-hsPDA group. The area under the ROC curve (AUC) value of the LUS on the fourth DOL was 0.94 (95% CI: 0.93–0.99) in predicting hsPDA. The LUS threshold at 33 achieved 89% sensitivity and 83% specificity, with the positive and negative predictive values (PPV and NPV) being 87 and 86%, respectively. The LUS can predict hsPDA in extremely preterm infants at an early stage.